Chemomab announces presentations at AASLD 2025 on nebokitug data

Chemomab Therapeutics (CMMB) announced that abstracts that highlight new clinical data from the nebokitug Phase 2 SPRING trial in primary sclerosing cholangitis, PSC, will be presented on November 10, 2025, at the American Association for the Study of Liver Disease, AASLD, The Liver Meeting 2025. Data presented from the SPRING trial open label extension, OLE, demonstrate continued and consistent effects of nebokitug on key inflammatory and fibrotic biomarkers, further reinforcing its disease-modifying potential in PSC. Two posters will present new clinical data that provides additional insights into the macrophage-related mechanism of action of nebokitug, a first-in-class antibody that inhibits the soluble protein CCL24, a key driver of disease processes in fibro-inflammatory diseases such as PSC. These results show that nebokitug may halt or slow disease progression and improve clinical outcomes – the primary objectives of the upcoming Phase 3 study.